MedTrace Logo

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL

NCT05350852 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-04-28

No results posted yet for this study

Summary

This is an open label, phase I study to assess the safety, efficacy and pharmacokinetics of ThisCART19A in patients with MRD+ B-ALL

Conditions

  • B-ALL

Interventions

BIOLOGICAL

ThisCART19A

ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • He Huang, Doctor · The first hospital affiliated Zhejiang University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-18
Primary Completion
2024-03-30
Completion
2024-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05350852 on ClinicalTrials.gov